AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33541535 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided group
Number of subjects: 1448
Study 33541535 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided group
Number of subjects: 1448
Study 616118509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB; 1.5 mg/0.06 cc)
Number of subjects: 45
Study 616118509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR; 0.5 mg/0.06 cc)
Number of subjects: 45
Study 616118509 — intervention group
Group type: COMPARATOR
Intervention: Focal DME
Number of subjects: 45
Study 34452594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nationwide epidemiologic survey of USH
Number of subjects: 1628
Study 34452594 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing and counseling for USH patients
Number of subjects: 1628
Study 33896402 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples Coping Enhancement Training (CCET)
Number of subjects: 80
Study 33896402 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 33206794 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) 150mg, two tablets daily
Number of subjects: 24
Study 33206794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 36419987 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta Medical's PEEK interference screw and EndoButton
Number of subjects: 104
Study 36419987 — intervention group
Group type: COMPARATOR
Intervention: Smith & Nephew's PEEK interference screw and EndoButton
Number of subjects: 104
Study 33080486 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose metronidazole (MTZ)
Number of subjects: 1477
Study 33080486 — intervention group
Group type: COMPARATOR
Intervention: Multidose metronidazole (MTZ)
Number of subjects: 1477
Study 33971288 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous intensity cycling (60 min)
Number of subjects: 30
Study 33971288 — intervention group
Group type: COMPARATOR
Intervention: Control (resting)
Number of subjects: 30
Study 33749456 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence statistics in percentage formats
Number of subjects: 0
Study 33749456 — intervention group
Group type: COMPARATOR
Intervention: No-message control group
Number of subjects: 0
Study 33934474 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel cream containing piroctone olamine, biosaccharide gum-2, stearyl glycyrrhetinate, and zinc l-pyrrolidone carboxylate, applied twice daily for 30 days
Number of subjects: 10
Study 36448321 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion gel formula (288 mg α-tocopherol)
Number of subjects: 12
Study 36448321 — intervention group
Group type: COMPARATOR
Intervention: Dry solid tablet (288 mg α-tocopherol)
Number of subjects: 12
Study 32121288 — intervention group
Group type: EXPERIMENTAL
Intervention: Health center staff training and home visits by community health volunteers
Number of subjects: 2494
Study 36041751 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 39
Study 36041751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 34398311 — intervention group
Group type: EXPERIMENTAL
Intervention: Peloidotherapy (heated mudpack at 41-42°C on painful and active joints, 5 days/week for 2 weeks)
Number of subjects: 56
Study 34398311 — intervention group
Group type: EXPERIMENTAL
Intervention: Peloidotherapy
Number of subjects: 56
Study 34398311 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 56
Study 35093068 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model based on 19 prognostic ferroptosis-related long noncoding RNAs (FRLs)
Number of subjects: 504
Study 35093068 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group based on risk score from the prognostic model
Number of subjects: 504
Study 35093068 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score from the prognostic model
Number of subjects: 504
Study 35093068 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of LUAD
Number of subjects: 504
Study 35093068 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of 34 checkpoint genes and 13 m6A-related genes
Number of subjects: 504
Study 32929841 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IM training)
Number of subjects: 50
Study 32929841 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 50
Study 32929841 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 35442196 — intervention group
Group type: EXPERIMENTAL
Intervention: CANreduce 2.0 intervention (self-guided web-based intervention, 6-week duration)
Number of subjects: 367
Study 35442196 — intervention group
Group type: EXPERIMENTAL
Intervention: CANreduce 2.0 intervention
Number of subjects: 367
Study 33299019 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA) cases confirmed by a rheumatologist based on 1987 ACR and/or 2010 ACR/EULAR criteria.
Number of subjects: 4916
Study 33299019 — intervention group
Group type: COMPARATOR
Intervention: Population-based cross-sectional study design.
Number of subjects: 4916
Study 35300670 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a culturally secure strategy for medical follow-up
Number of subjects: 0
Study 35300670 — intervention group
Group type: COMPARATOR
Intervention: Health information only control group
Number of subjects: 0
Study 35300670 — intervention group
Group type: COMPARATOR
Intervention: Nil-intervention control group
Number of subjects: 0
Study 34710946 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrosomial iron (60 mg/day for one month)
Number of subjects: 1000
Study 34958092 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 g of MCH applied as SPLAT MCH (SPLAT3.5)
Number of subjects: 91
Study 34958092 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 g of Acer kairomone blend (AKB)
Number of subjects: 91
Study 34958092 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 g of acetophenone + green leaf volatiles (PLUS)
Number of subjects: 91
Study 34958092 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g of MCH applied as SPLAT MCH (SPLAT7)
Number of subjects: 91
Study 34958092 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g of Acer kairomone blend (AKB)
Number of subjects: 91
Study 34958092 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g of acetophenone + green leaf volatiles (PLUS)
Number of subjects: 91
Study 34958092 — intervention group
Group type: COMPARATOR
Intervention: Baited control (bait only)
Number of subjects: 91
Study 32978193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadaveric simulation training
Number of subjects: 0
Study 32978193 — intervention group
Group type: COMPARATOR
Intervention: Standard 'on-the-job' training
Number of subjects: 0
Study 35626843 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted dental visual aids
Number of subjects: 64
Study 35626843 — intervention group
Group type: COMPARATOR
Intervention: Regular dental visual aids
Number of subjects: 64
Study 32118826 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhage + CRM (n = 22)
Number of subjects: 77
Study 32118826 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhage (n = 31)
Number of subjects: 77
Study 32118826 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 24)
Number of subjects: 77
Study 32354661 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuum beliefs induced with videos supporting a continuum viewpoint of schizophrenia
Number of subjects: 565
Study 32354661 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorial beliefs induced with videos supporting a categorial viewpoint of schizophrenia
Number of subjects: 565
Study 32354661 — intervention group
Group type: COMPARATOR
Intervention: Neutral video (control group)
Number of subjects: 565
Study 34551129 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT)
Number of subjects: 100
Study 34551129 — intervention group
Group type: COMPARATOR
Intervention: Watchful Waiting (WW)
Number of subjects: 100
Study 34551129 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 100
Study 33148601 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective monitoring of outcomes using control charts with regular feedback on indicators (intervention group)
Number of subjects: 155362
Study 33148601 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (control group)
Number of subjects: 155362
Study 36093579 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-headed toothbrush (Curaprox CS 5460)
Number of subjects: 20
Study 36093579 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothbrush (ultrasoft)
Number of subjects: 20
Study 33184151 — intervention group
Group type: EXPERIMENTAL
Intervention: Habits-GDM smartphone application coaching program
Number of subjects: 340
Study 33184151 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 340
Study 32022286 — intervention group
Group type: EXPERIMENTAL
Intervention: Glepaglutide 10 mg
Number of subjects: 18
Study 32022286 — intervention group
Group type: EXPERIMENTAL
Intervention: Glepaglutide
Number of subjects: 18
Study 36307156 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment manoeuvres (RMs) with sequential high-flow nasal oxygen therapy (HFNO) after extubation
Number of subjects: 654
Study 36307156 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 654
Study 34159536 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI‐FES group
Number of subjects: 32
Study 34159536 — intervention group
Group type: COMPARATOR
Intervention: NMES group
Number of subjects: 32
Study 32156696 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary ciliary dyskinesia (PCD)
Number of subjects: 333
Study 32156696 — intervention group
Group type: COMPARATOR
Intervention: Cystic fibrosis (CF)
Number of subjects: 333
Study 34465344 — intervention group
Group type: COMPARATOR
Intervention: Sanitary pad distribution
Number of subjects: 3489
Study 34465344 — intervention group
Group type: COMPARATOR
Intervention: Reproductive health education
Number of subjects: 3489
Study 34465344 — intervention group
Group type: COMPARATOR
Intervention: Both sanitary pad distribution and reproductive health education
Number of subjects: 3489
Study 32493335 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5380
Study 35721715 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics nomogram combining Rad-score and clinical risk factors (radiologists' interpretation)
Number of subjects: 153
Study 35721715 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics models (K-nearest neighbor, logistic regression, decision tree, linear-SVM, gaussian-SVM, polynomial-SVM)
Number of subjects: 153
Study 34959887 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 1059
Study 34959887 — intervention group
Group type: EXPERIMENTAL
Intervention: Other FoPLs
Number of subjects: 1059
Study 34959887 — intervention group
Group type: COMPARATOR
Intervention: No label condition
Number of subjects: 1059
Study 34838889 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional counseling every 2 weeks
Number of subjects: 58
Study 34838889 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional counseling)
Number of subjects: 58
Study 34838889 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 58
Study 33297608 — intervention group
Group type: EXPERIMENTAL
Intervention: PKP concurrently combined with ZOL
Number of subjects: 600
Study 33297608 — intervention group
Group type: COMPARATOR
Intervention: PKP alone
Number of subjects: 600
Study 33297608 — intervention group
Group type: COMPARATOR
Intervention: PKP combined with ZOL 1 month later
Number of subjects: 600
Study 35158230 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg lysergic acid diethylamide (LSD)
Number of subjects: 24
Study 35158230 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 24
Study 35428571 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-friendly audiovisual (AV) system
Number of subjects: 61
Study 35428571 — intervention group
Group type: COMPARATOR
Intervention: Standard system (control)
Number of subjects: 61
Study 32443412 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified complementary food supplements (CFSs)
Number of subjects: 752
Study 32443412 — intervention group
Group type: EXPERIMENTAL
Intervention: Two of the four CFSs
Number of subjects: 752
Study 32443412 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 752
Study 35622456 — intervention group
Group type: EXPERIMENTAL
Intervention: E2027 (doses ranging from 5 to 1200 mg)
Number of subjects: 0
Study 35622456 — intervention group
Group type: EXPERIMENTAL
Intervention: E2027 (doses planned for phase 2 study)
Number of subjects: 0
Study 33229934 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine e-cigarettes as a cessation strategy (among participants attempting to quit, N = 137)
Number of subjects: 179
Study 34773634 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine/Tadalafil (DT)
Number of subjects: 120
Study 34773634 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine/Tadalafil (PT)
Number of subjects: 120
Study 34773634 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine (Da)
Number of subjects: 120
Study 34773634 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (Pa)
Number of subjects: 120
Study 32590151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 165
Study 34245744 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral drug therapy
Number of subjects: 50
Study 36444953 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen before removal of drainage tubes and a second dose at 8 p.m. on the same day.
Number of subjects: 183
Study 36444953 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment without acetaminophen (control group).
Number of subjects: 183
Study 35852641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 38
Study 35852641 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression therapy
Number of subjects: 38
Study 35852641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (nab-PTX)
Number of subjects: 38
Study 33046345 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 119
Study 33046345 — intervention group
Group type: COMPARATOR
Intervention: Standard Dressings
Number of subjects: 119
Study 35583268 — intervention group
Group type: EXPERIMENTAL
Intervention: iADAPT application
Number of subjects: 31
Study 35583268 — intervention group
Group type: COMPARATOR
Intervention: Workbook
Number of subjects: 31
Study 33594991 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective expectancy‐only condition
Number of subjects: 132
Study 33594991 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective expectancy‐only condition
Number of subjects: 132
Study 33594991 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined expectancy condition
Number of subjects: 132
Study 33594991 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 132
Study 35193648 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch (HES) 130 solution (Volulyte 6%, Fresenius Kabi, Germany)
Number of subjects: 2280
Study 35193648 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid solution (Ionolyte, Fresenius Kabi, Germany)
Number of subjects: 2280
Study 34167639 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 18846
Study 34167639 — intervention group
Group type: COMPARATOR
Intervention: Nonuse of statins
Number of subjects: 18846
Study 32173766 — intervention group
Group type: EXPERIMENTAL
Intervention: M-VO2peak (38 min of cycling at 70% VO2peak)
Number of subjects: 40
Study 32173766 — intervention group
Group type: EXPERIMENTAL
Intervention: M-IAT (38 min of cycling at 97% of individual anaerobic lactate threshold)
Number of subjects: 40
Study 32173766 — intervention group
Group type: EXPERIMENTAL
Intervention: M-VT (38 min of cycling at 67% between ventilatory thresholds 1 and 2)
Number of subjects: 40
Study 35979057 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol intravenous anesthesia combined with press-needle therapy
Number of subjects: 128
Study 35979057 — intervention group
Group type: COMPARATOR
Intervention: Propofol intravenous anesthesia
Number of subjects: 128
Study 33878522 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Audiovisual Stimulation (AVS) for 30 minutes at bedtime (n = 15)
Number of subjects: 30
Study 33878522 — intervention group
Group type: COMPARATOR
Intervention: Placebo control for 30 minutes at bedtime (n = 15)
Number of subjects: 30
Study 33259540 — intervention group
Group type: EXPERIMENTAL
Intervention: Core warming via an esophageal heat exchanger
Number of subjects: 20
Study 33259540 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 20
Study 36329189 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicruciate-retaining (BCR) prostheses
Number of subjects: 77
Study 36329189 — intervention group
Group type: COMPARATOR
Intervention: Posterior-stabilized (PS) prostheses
Number of subjects: 77
Study 34297713 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon array
Number of subjects: 407
Study 34297713 — intervention group
Group type: COMPARATOR
Intervention: Bar graph
Number of subjects: 407
Study 35762946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia (CBTi)
Number of subjects: 102
Study 35762946 — intervention group
Group type: COMPARATOR
Intervention: Audiology-Based Care (ABC)
Number of subjects: 102
Study 35762946 — intervention group
Group type: COMPARATOR
Intervention: Sleep Support Group (SSG)
Number of subjects: 102
Study 33622954 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Number of subjects: 46
Study 33622954 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 46
Study 33152700 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD‐MTX; 3‐8 g/m2)
Number of subjects: 0
Study 33152700 — intervention group
Group type: EXPERIMENTAL
Intervention: HD‐MTX-based therapy
Number of subjects: 0
Study 33152700 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel regimens (ibrutinib, lenalidomide + rituximab)
Number of subjects: 0
Study 33152700 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous stem cell transplantation
Number of subjects: 0
Study 33152700 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain radiation therapy
Number of subjects: 0
Study 35624433 — intervention group
Group type: EXPERIMENTAL
Intervention: New prognostic model for overall survival (OS) based on IPI, β2-microglobulin, platelet count, and red blood cell distribution width.
Number of subjects: 998
Study 34313842 — intervention group
Group type: EXPERIMENTAL
Intervention: Gay-specific Trier Social Stress Test (TSST)
Number of subjects: 33
Study 34313842 — intervention group
Group type: COMPARATOR
Intervention: General Trier Social Stress Test (TSST)
Number of subjects: 33
Study 32358381 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study 32358381 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 0
Study 35502662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 5091
Study 35502662 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 5091
Study 33481780 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) for soil-transmitted helminths (STH)
Number of subjects: 0
Study 35258400 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 486
Study 35258400 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Advice (BA)
Number of subjects: 486
Study 35258400 — intervention group
Group type: COMPARATOR
Intervention: Screening Control (SC)
Number of subjects: 486
Study 35258400 — intervention group
Group type: COMPARATOR
Intervention: Non-Screening Control (NSC)
Number of subjects: 486
Study 33724256 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib augmentation (n = 18)
Number of subjects: 27
Study 33724256 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (n = 9)
Number of subjects: 27
Study 33371159 — intervention group
Group type: EXPERIMENTAL
Intervention: Shi-style spine balance manipulation combined with Daoyin therapy
Number of subjects: 72
Study 33371159 — intervention group
Group type: COMPARATOR
Intervention: Lumbar mechanical traction
Number of subjects: 72
Study 35758335 — intervention group
Group type: EXPERIMENTAL
Intervention: Pair-switching rerandomization (PSRR)
Number of subjects: 0
Study 35758335 — intervention group
Group type: COMPARATOR
Intervention: Classical rerandomization
Number of subjects: 0
Study 34143559 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation
Number of subjects: 12
Study 34143559 — intervention group
Group type: COMPARATOR
Intervention: Medical air (control)
Number of subjects: 12
Study 32297875 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered, internet-based messaging intervention (educational and motivational messages) over 12 weeks.
Number of subjects: 244
Study 33834521 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4-mg plus TCS
Number of subjects: 329
Study 33834521 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2-mg plus TCS
Number of subjects: 329
Study 33834521 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus TCS
Number of subjects: 329
Study 33560442 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy with rituximab
Number of subjects: 199
Study 33560442 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy without rituximab
Number of subjects: 199
Study 33560442 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-Gy whole-brain radiotherapy (WBRT)
Number of subjects: 199
Study 33560442 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in white matter abnormalities and cerebral atrophy
Number of subjects: 199
Study 36377367 — intervention group
Group type: EXPERIMENTAL
Intervention: NEW‐R intervention
Number of subjects: 113
Study 36377367 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 113